Key players in the metabolic disorder drug market include Novo Nordisk, Eli Lilly And Company, Novartis AG, Sanofi SA, Merck & Co., GlaxosmithKline, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, and Dainippon Sumitomo Pharma.
New York, March 04, 2022 (GLOBE NEWSWIRE) — Reportlinker.com Announces Release of “Metabolic Disorders Drugs Global Market Report 2022” – https://www.reportlinker.com/p06241976/?utm_source=GNW
The global metabolic disorder drug market is expected to grow from $82.05 billion in 2021 to $90.83 billion in 2022 at a compound annual growth rate (CAGR) of 10.7%. The growth is mainly due to companies reorganizing their operations and recovering from the impact of COVID-19, which had previously led to restrictive containment measures involving social distancing, remote working and the closure of business activities that resulted in operational challenges. The market is expected to reach $129.40 billion in 2026 with a CAGR of 9.3%.
The metabolic disorder drugs market includes sales of metabolic disorder drugs and related services by entities (organizations, individual traders, and partnerships) that produce metabolic disorder drugs to treat metabolic diseases. This industry includes establishments that produce drugs such as insulin, pramlintide, and other drugs. to treat diabetes, antithyroid medicines to treat hyperthyroidism and other medicines to treat disorders of the pituitary gland, adrenal gland and parathyroid gland.
The metabolic disorders drug market is segmented into anti-diabetic, anti-thyroid and other (hyperparathyroidism, hypopituitarism, hypoadrenalism) drugs.
The main types of drugs for metabolic disorders are antidiabetic drugs, antithyroid drugs, antiobesity and others (hyperparathyroidism, hypopituitarism, hypoadrenalism). Antithyroid drugs are drugs that reduce the synthesis of thyroid hormones (thionamides) or increase the release of thyroid hormones (iodides). .
Medicines are available as pharmaceutical drugs and biologics. Drugs are administered orally, parenterally and others which are classified into branded and generic drugs.
The various modes of purchase include prescription drugs and over-the-counter drugs that are dispensed by hospital pharmacies, retail pharmacies/pharmacies and others.
North America was the largest region in the metabolic disorder drug market in 2021. Middle East is expected to be the fastest growing region during the forecast period.
Regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Rising sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the global population, particularly non-communicable diseases such as diabetes and obesity. Long working hours, reduced physical activity and poor eating and drinking habits are the main causes. metabolic disorders.
According to the World Health Organization, the prevalence of chronic diseases increased by 57% globally in 2020. These factors are expected to increase the number of patients globally, thereby driving the metabolic disorder drug market over the course of the forecast period.
Regulatory agencies and federal governments have passed strict regulations and taken a tough stance on drug pricing by pharmaceutical companies. Pharmaceutical companies have been criticized by politicians, patients and doctors over the high prices of certain medicines and drugs.
In addition, companies had to sell drugs and medicines at subsidized rates to public hospitals, doctors and clinics, which further affected the companies’ revenue. This has led drug manufacturing companies to operate with a reduced profit margin.
These factors will negatively impact the attractiveness of the Metabolic Disorder Drugs industry during the forecast period.
Companies are focused on using artificial intelligence applications to revolutionize the treatment of metabolic disorders. Artificial intelligence is machine-based learning that uses human intelligence features like reasoning and problem-solving abilities to gain insights and provide useful insights.
This technology radically changes the treatment of metabolic syndrome by analyzing large chemical and biological datasets to identify potential drug candidates with higher success rates and at a faster rate compared to human analysis. 3BIGS, a Korean bio-data analytics company that studies the relationship between diseases, targets and drugs, is using AI technology to help researchers reuse drugs for other diseases.
The countries covered in the Metabolic Disorder Drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland. , Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, United Arab Emirates, United Kingdom, United States, Venezuela and Vietnam.
Read the full report: https://www.reportlinker.com/p06241976/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.
CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001